EGFR and neoplasm: Interestingly, recent results from clinical trials involving nimotuzumab, a new anti-EGFR monoclonal antibody, have reported to have lesser or no skin toxicity which has been postulated to be secondary to selective inhibition for tumor cell EGFR phosphorylation only while sparing the skin [36–38].